Antiproliferative B cell translocation gene 2 protein is down-regulated post-transcriptionally as an early event in prostate carcinogenesis.

B cell translocation gene 2 (BTG2) is a p53 target that negatively regulates cell cycle progression in response to DNA damage and other stress. The objective of this study was to examine the expression, regulation and tumor suppressor properties of BTG2 in prostate cells. By immunohistochemistry BTG2 protein was detected in approximately 50% of basal cells in benign glands from the peripheral zone of the human prostate. BTG2 was expressed in all hyperproliferative atrophic peripheral zone lesions examined (simple atrophy, post-atrophic hyperplasia and proliferative inflammatory atrophy), but was undetectable or detectable at very low levels in the hyperproliferative epithelial cells of HGPIN and prostate cancer. BTG2 mRNA was detected in non-malignant prostate epithelial (PE) cells and in LNCaP cells, but not in PC-3 cells, consistent with p53-dependent regulation. In PE cells BTG2 protein was detected in areas of cell confluence by immunohistochemistry. BTG2 protein in LNCaP cells was undetectable by immunohistochemistry but was detected by immunoblotting at 8- to 9-fold lower levels than in PE cells. BTG2 protein levels were shown to be regulated by the ubiquitin-proteosome system. Forced expression of BTG2 in PC-3 cells was accompanied by a decreased rate of cell proliferation and decreased tumorigenicity of these cells in vivo. Taken together, these findings suggest that BTG2 functions as a tumor suppressor in prostate cells that is activated by cell quiescence, cell growth stimuli as part of a positive feedback mechanism and in response to DNA damage or other cell stress. The low steady-state levels of BTG2 protein in HGPIN and prostate cancer, a potential consequence of increased proteosomal degradation, may have important implications in the initiation and progression of malignant prostate lesions. Furthermore, these findings suggest that a significant component of the p53 G(1) arrest pathway might be inactivated in prostate cancer even in the absence of genetic mutations in p53.

[1]  D. Guardavaccaro,et al.  Arrest of G1-S Progression by the p53-Inducible Gene PC3 Is Rb Dependent and Relies on the Inhibition of Cyclin D1 Transcription , 2000, Molecular and Cellular Biology.

[2]  P. Hainaut,et al.  BTG gene expression in the p53‐dependent and ‐independent cellular response to DNA damage , 2000, Molecular carcinogenesis.

[3]  T. Voeltzel,et al.  The Leukemia-associated Protein Btg1 and the p53-regulated Protein Btg2 Interact with the Homeoprotein Hoxb9 and Enhance Its Transcriptional Activation* , 2000, The Journal of Biological Chemistry.

[4]  J. Epstein,et al.  Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. , 1999, The American journal of pathology.

[5]  M. Kattan,et al.  Postatrophic Hyperplasia of the Prostate , 1999 .

[6]  M. Kattan,et al.  Postatrophic hyperplasia of the prostate: lack of association with prostate cancer. , 1999, The American journal of surgical pathology.

[7]  F. Christians,et al.  Induction of GADD45 and JNK/SAPK-Dependent Apoptosis following Inducible Expression of BRCA1 , 1999, Cell.

[8]  H. Lepor,et al.  Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. , 1999, The Journal of urology.

[9]  A. Budde,et al.  p53 represses ribosomal gene transcription , 1999, Oncogene.

[10]  Bernhard O. Palsson,et al.  Cancer cell lines , 1999 .

[11]  D. Sukovich,et al.  Human carbon catabolite repressor protein (CCR4)-associative factor 1: cloning, expression and characterization of its interaction with the B-cell translocation protein BTG1. , 1998, The Biochemical journal.

[12]  H. Lepor,et al.  Identification of genes associated with stromal hyperplasia and glandular atrophy of the prostate by mRNA differential display. , 1998, Experimental cell research.

[13]  T. Park,et al.  Induction of growth inhibition of 293 cells by downregulation of the cyclin E and cyclin‐dependent kinase 4 proteins due to overexpression of TIS21 , 1998, Molecular carcinogenesis.

[14]  J. Epstein,et al.  Histology and cellular kinetics of prostatic atrophy. , 1998, The American journal of surgical pathology.

[15]  J. Magaud,et al.  Interaction of BTG1 and p53-regulatedBTG2 Gene Products with mCaf1, the Murine Homolog of a Component of the Yeast CCR4 Transcriptional Regulatory Complex* , 1998, The Journal of Biological Chemistry.

[16]  H. Lepor,et al.  Endothelin‐1 production and agonist activities in cultured prostate‐derived cells: Implications for regulation of endothelin bioactivity and bioavailability in prostatic hyperplasia , 1998, The Prostate.

[17]  M L Agarwal,et al.  The p53 Network* , 1998, The Journal of Biological Chemistry.

[18]  W. Fair,et al.  Evaluation of the tetracycline‐repressible transactivator system for inducible gene expression in human prostate cancer cell lines , 1997, The Prostate.

[19]  K. Kimura,et al.  Rapid induction of Fas antigen mRNA expression in vivo by cycloheximide , 1997 .

[20]  L. Duret,et al.  Cloning of the mouse BTG3 gene and definition of a new gene family (the BTG family) involved in the negative control of the cell cycle , 1997, Leukemia.

[21]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[22]  Stephen S. Sternberg,et al.  Histology for Pathologists , 1992, Annals of Internal Medicine.

[23]  K. Kimura,et al.  Rapid induction of Fas antigen mRNA expression in vivo by cycloheximide. , 1997, Cell biochemistry and function.

[24]  R. Berger,et al.  Identification of BTG2, an antiproliferative p53–dependent component of the DNA damage cellular response pathway , 1996, Nature Genetics.

[25]  R. Kirby,et al.  Ki-67 expression in early prostate cancer and associated pathological lesions. , 1996, Journal of clinical pathology.

[26]  S. Clarke,et al.  The Mammalian Immediate-early TIS21 Protein and the Leukemia-associated BTG1 Protein Interact with a Protein-arginine N-Methyltransferase* , 1996, The Journal of Biological Chemistry.

[27]  M. Loda,et al.  Cell cycle and cancer: critical events at the G1 restriction point. , 1996, Critical reviews in oncogenesis.

[28]  K. Kinzler,et al.  p21 is necessary for the p53-mediated G1 arrest in human cancer cells. , 1995, Cancer research.

[29]  James Brugarolas,et al.  Radiation-induced cell cycle arrest compromised by p21 deficiency , 1995, Nature.

[30]  J. Cheville,et al.  Postatrophic Hyperplasia of the Prostate: A Histologic Mimic of Prostatic Adenocarcinoma , 1995, The American journal of surgical pathology.

[31]  G. Stark,et al.  p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Stephen J. Elledge,et al.  Mice Lacking p21 CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control , 1995, Cell.

[33]  R F Standaert,et al.  Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin , 1995, Science.

[34]  R W Veltri,et al.  Implication of cell kinetic changes during the progression of human prostatic cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  N. Colburn,et al.  Preferential primary‐response gene expression in promotion‐resistant versus promotion‐sensitive JB6 cells , 1994, Molecular carcinogenesis.

[36]  Tom Maniatis,et al.  The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB , 1994, Cell.

[37]  A. Goldberg,et al.  Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules , 1994, Cell.

[38]  J. Veldscholte,et al.  Studies on the human prostatic cancer cell line LNCaP , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[39]  S. Schreiber,et al.  A beta-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  E. Harlow,et al.  Identification of G1 kinase activity for cdk6, a novel cyclin D partner , 1994, Molecular and cellular biology.

[41]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[42]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[43]  W. W. Nichols,et al.  p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. , 1993, Journal of the National Cancer Institute.

[44]  D. S. Coffey.  Prostate cancer. An overview of an increasing dilemma , 1993, Cancer.

[45]  Steven K. Hanks,et al.  Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins , 1992, Cell.

[46]  G. M. Ledda-Columbano,et al.  Rapid induction of apoptosis in rat liver by cycloheximide. , 1992, The American journal of pathology.

[47]  J. Simard,et al.  Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. , 1991, Cancer research.

[48]  R. Koski,et al.  Structure and expression of TIS21, a primary response gene induced by growth factors and tumor promoters. , 1991, The Journal of biological chemistry.

[49]  E. Shooter,et al.  Molecular cloning of PC3, a putatively secreted protein whose mRNA is induced by nerve growth factor and depolarization. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[50]  N. Katunuma,et al.  Inhibitory effect of di- and tripeptidyl aldehydes on calpains and cathepsins. , 1990, Journal of enzyme inhibition.

[51]  Phang-lang Chen,et al.  Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation , 1989, Cell.

[52]  David M. Livingston,et al.  The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element , 1989, Cell.

[53]  E. Harlow,et al.  The retinoblastoma protein is phosphorylated during specific phases of the cell cycle , 1989, Cell.

[54]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[55]  L. Lau,et al.  Expression of a set of growth-related immediate early genes in BALB/c 3T3 cells: coordinate regulation with c-fos or c-myc. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Greenberg,et al.  Effect of protein synthesis inhibitors on growth factor activation of c-fos, c-myc, and actin gene transcription , 1986, Molecular and cellular biology.

[57]  P. Walsh,et al.  The development of human benign prostatic hyperplasia with age. , 1984, The Journal of urology.

[58]  P. Leder,et al.  Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor , 1983, Cell.

[59]  J. McNeal.  The zonal anatomy of the prostate , 1981, The Prostate.

[60]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[61]  L. M. Franks.  Atrophy and hyperplasia in the prostate proper. , 1954, The Journal of pathology and bacteriology.

[62]  Franks Lm.  Benign nodular hyperplasia of the prostate; a review. , 1954 .

[63]  L. M. Franks.  Benign nodular hyperplasia of the prostate; a review. , 1953, Annals of the Royal College of Surgeons of England.

[64]  J. McNeal,et al.  The zonal anatomy of the prostate , 1981, The Prostate.